乌梅丸加减治疗原发性肝癌TACE术后综合征的疗效及对AFP、MMP-9水平的影响OA
The efficacy of modified Wumei pill on TACE postoperative syndrome in primary hepatic carcinoma and its impacts on AFP and MMP-9 levels
目的:探讨乌梅丸加减治疗原发性肝癌(PHC)经导管肝动脉化疗栓塞(TACE)术后综合征的疗效及对甲胎蛋白(AFP)、基质金属蛋白酶-9(MMP-9)水平的影响.方法:选取2023年1月至2024年3月收治的100例发生TACE术后综合征的PHC患者为研究对象,根据随机数字表法将患者分成两组,对照组50例,行常规治疗;观察组50例,在对照组常规治疗基础上联用乌梅丸加减方,疗程均为2周.治疗结束后,比较两组患者临床疗效、中医证候积分、生活质量、肿瘤标志物、血管生成因子、基质调节因子、肝功能表达水平差异.结果:对照组患者总有效率低于观察组(P＜0.05).两组患者治疗后中医证候积分(如发热、恶心呕吐等)、AFP、癌胚抗原(CEA)、总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)表达水平均降低,且观察组低于对照组(P＜0.05).两组患者治疗后卡氏(KPS)评分较治疗前升高,且观察组高于对照组(P＜0.05).两组患者治疗后碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)、MMP-9水平较治疗前降低,且观察组均低于对照组(P＜0.05).结论:乌梅丸加减治疗PHC患者TACE术后综合征,可显著调节AFP、MMP-9表达水平,缓解临床症状,改善肝功能,提高患者生活质量,具有进一步推广使用的潜力.
Objective:To investigate the efficacy of modified Wumei pill on postoperative syndrome of primary hepatic carcinoma(PHC)after transcatheter arterial chemoembolization(TACE)and its impacts on levels of alpha fetoprotein(AFP)and matrix metalloproteinase-9(MMP-9).Methods:This study selected 100 PHC patients with TACE postoperative syndrome admitted from January 2023 to March 2024 as the research subjects.According to the random number table method,the patients were assigned into two groups:a control group of 50 cases(conventional treatment)and an observation group of 50 cases(treated with modified Wumei pill based on the control group).After the treatment was completed,the efficacy of the two groups was compared.Meantime,the differences in traditional Chinese medicine syndrome scores,quality of life,tumor markers,angiogenic factors,matrix regulatory factors,and liver function between the control group and the observation group were observed.Results:The total effective rate of the control group was lower than that of the observation group(P＜0.05).After treatment,the scores of various traditional Chinese medicine syndromes(such as fever,nausea and vomiting),and the levels of AFP,carcinoembryonic antigen,total bilirubin,alanine aminotransferase,and aspartate aminotransferase in both groups decreased,and those in the observation group were lower than those in the control group(P＜0.05).After treatment,the Karnofsky performance status(KPS)scores of both groups increased compared to before treatment,and with the observation group being higher than the control group(P＜0.05).After treatment,the levels of basic fibroblast growth factor,vascular endothelial growth factor,and MMP-9 in both groups decreased compared to before treatment,and those in the observation group were lower than those in the control group(P＜0.05).Conclusion:The modified Wumei pill can obviously regulate the levels of AFP and MMP-9,alleviate clinical symptoms,improve liver function,and enhance the quality of life of PHC patients with TACE postoperative syndrome.Therefore,it has the potential for further promotion and use.
朱晓婷;刘新华;徐海霞;王菲;张婧;李金良;闫志荣
唐山市人民医院中医科(河北 唐山,063001)唐山市人民医院,乔屯社区卫生服务中心唐山市丰润区人民医院肠道外科唐山市人民医院病案管理科唐山市人民医院肝胆外科唐山市人民医院神经康复科开滦总医院康复医院药剂科
医药卫生
原发性肝癌乌梅丸经导管肝动脉化疗栓塞甲胎蛋白基质金属蛋白酶-9
Wumei pillprimary hepatic carcinomatranscatheter artery chemoembolizationalpha fetoproteinmatrix metalloproteinase 9
《中西医结合肝病杂志》 2026 (2)
139-143,5
河北省中医药管理局科研计划项目(No.2024433)
评论